Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Using discrete disease status as the phenotype and computing statistics at the single marker level may not be able to address the underlying biological interactions that contribute to disease mechanism and may contribute to the issue of “missing heritability.” We performed a genome-wide association study (GWAS) and a genome-wide interaction study (GWIS) of an amyloid imaging phenotype, using the data from Alzheimer's Disease Neuroimaging Initiative. We investigated the genetic main effects and interaction effects on cingulate amyloid-beta (Aβ) load in an effort to better understand the genetic etiology of Aβ deposition that is a widely studied AD biomarker. PLINK was used in the single marker GWAS, and INTERSNP was used to perform the two-marker GWIS, focusing only on SNPs with p ≤ 0.01 for the GWAS analysis. Age, sex, and diagnosis were used as covariates in both analyses. Corrected p values using the Bonferroni method were reported. The GWAS analysis revealed significant hits within or proximal to APOE, APOC1, and TOMM40 genes, which were previously implicated in AD. The GWIS analysis yielded 8 novel SNP-SNP interaction findings that warrant replication and further investigation.

[1]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[2]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[3]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[4]  Masanori Kato,et al.  Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease , 1993, Neuroscience Letters.

[5]  J. Hardy,et al.  A nonsense mutation in PRNP associated with clinical Alzheimer's disease , 2014, Neurobiology of Aging.

[6]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[7]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[8]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[9]  O. Combarros,et al.  Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer's disease risk. , 2010, Journal of Alzheimer's disease : JAD.

[10]  O. Combarros,et al.  Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK‐3β) and Alzheimer’s disease risk , 2009, Acta neurologica Scandinavica.

[11]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[12]  D. G. Clark,et al.  Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease , 2011 .

[13]  Michael W. Weiner,et al.  APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study , 2013, Molecular Psychiatry.

[14]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[15]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[16]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[17]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[18]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[19]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[20]  Paul M. Thompson,et al.  Transcriptomics of cortical gray matter thickness decline during normal aging , 2013, NeuroImage.

[21]  Pinchas Cohen,et al.  Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Andrew J. Saykin,et al.  Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease , 2009, PloS one.

[23]  Jason H. Moore,et al.  Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers , 2013, Brain Imaging and Behavior.

[24]  Tricia A. Thornton-Wells,et al.  Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography , 2013, Human Genetics.

[25]  S. Potkin,et al.  Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: Methodological considerations , 2009, Cognitive neuropsychiatry.

[26]  Michael Weiner,et al.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.

[27]  R. Petersen,et al.  Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease , 2010, Human Genetics.

[28]  O. Combarros,et al.  Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk , 2009, Brain Research.

[29]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[30]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[31]  Tim Becker,et al.  INTERSNP: genome-wide interaction analysis guided by a priori information , 2009, Bioinform..

[32]  Tricia A. Thornton-Wells,et al.  Genetic Interactions Associated with 12-month Atrophy in Hippocampus and Entorhinal Cortex in Alzheimer's Disease Neuroimaging Initiative , for the Alzheimer's Disease Neuroimaging Initiative , 2022 .

[33]  J. Trojanowski,et al.  Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.

[34]  Nick C Fox,et al.  Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .

[35]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[36]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[37]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[38]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[39]  T. Yen,et al.  Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [18F]AV-45 Positron Emission Tomography in Chinese Population , 2013, PloS one.

[40]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[41]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[42]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[43]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[44]  V Shane Pankratz,et al.  Replication of BIN1 association with Alzheimer's disease and evaluation of genetic interactions. , 2011, Journal of Alzheimer's disease : JAD.

[45]  Simon Lovestone,et al.  Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) , 2012, Neurobiology of Aging.

[46]  W. Marsden.  I and J , 2012 .

[47]  Michelle K. Lupton,et al.  Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease , 2014, Neurobiology of Aging.

[48]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[49]  M. Nalls,et al.  Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype , 2013, Biological Psychiatry.